Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio
Key Highlights
- ➤PrTK05 showed systemic cytotoxic T-cell activation after intraprostatic aglatimagene administration.
- ➤NSCLC median overall survival reached 25.4 months; 23 patients survived 24 months.
- ➤NSCLC biomarkers and immune profiles were associated with survival beyond 24 months.
- ➤Linoserpaturev recurrent glioblastoma median survival reached 14.3 months after repeated administration.
- ➤Bevacizumab analysis showed no statistically significant overall survival improvement after linoserpaturev.
Expert Statements
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“The PrTK05 findings show that adding aglatimagene to standard-of-care can generate a systemic cytotoxic T-cell response that was not observed with radiation-based standard of care alone”
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“Together with biodistribution and shedding results that are consistent with our earlier studies, these data strengthen the mechanistic package we plan to include in the BLA submission for aglatimagene in localized prostate cancer.”
Garrett Nichols, Chief Medical Officer of Candel Therapeutics
“These multi-omic analyses connect longitudinal immune changes in blood and tumor tissue with clinical outcomes in patients whose disease had remained stable or progressed despite checkpoint inhibition,”
Garrett Nichols, Chief Medical Officer of Candel Therapeutics
“Although these findings are associative, their consistency across complementary biomarker measures adds to the biological rationale for evaluating aglatimagene in the ongoing phase 3 AURORA trial in metastatic non-squamous NSCLC.”
Francesca Barone, Chief Scientific Officer of Candel Therapeutics
“The updated survival data following both single and repeated linoserpaturev administration are encouraging in a disease with persistently poor outcomes,”
Francesca Barone, Chief Scientific Officer of Candel Therapeutics
“Importantly, the tissue analyses are also helping us identify biologically grounded strategies that may further enhance and sustain antitumor activity.”
Francesca Barone, Chief Scientific Officer of Candel Therapeutics
“The bevacizumab analysis is exploratory and does not establish benefit, but it provides a clear hypothesis for prospective evaluation as we refine the development strategy for linoserpaturev in recurrent glioblastoma.”
Three posters, including a late-breaking presentation, provide new clinical and biomarker data for aglatimagene besadenovec (aglatimagene) in localized prostate cancer and non-small cell lung cancer (NSCLC), and for linoserpaturev in recurrent glioblastoma * PrTK05 data show systemic cytotoxic T-cell activation following intraprostatic administration of aglatimagene in intermediate-risk localized prostate cancer, together with data consistent with transient biodistribution and shedding, supporting the planned BLA submission
* In progressive non-squamous NSCLC, longitudinal immune changes in blood and tumor tissue and specific multi-omic features were associated with survival beyond 24 months, supporting the biological rationale for the ongoing phase 3 AURORA trial
Get started
Create a free account to read the full story.